ClinicalTrials.gg
RecruitingNCT07133750Updated Jul 23, 2026

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of PM8002 and Chemotherapy Regimen 1 in CRC (Colorectal Cancer), sponsored by Biotheus Inc.. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 603 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
375th of 891
100 · median 80
Started
2025
with 124 others
Phase 2
349 of 1,136
177 open now
Primary completion
2027-05
later than 380 of 602 live
Registered
946th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 375th largest by planned enrollment of the 891 interventional ones that give a count, is one of 125 that started in 2025, is one of 349 in phase 2, reaches primary completion later than 380 of the 602 other live ones, and was the 946th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.

Read the detailed description

A multicenter, randomized, open-label study design is used, with a planned enrollment of 100 participants, 40 in the PM8002 (BNT327)+ chemotherapy regimen 1 group, 30 in the PM8002 (BNT327)+ chemotherapy regimen 2 group and 30 in the PM8002 (BNT327)+ chemotherapy regimen 3 group. The investigators make the decision on which chemotherapy regimen to be used in the participants. After combined chemotherapy regimen is confirmed, participants will be randomized to one of two dose levels of PM8002(BNT327) plus chemotherapy.

03

Conditions studied

  • CRC (Colorectal Cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Signed form before any trial-related processes.
  2. Age ≥ 18 years male or female.
  3. or cytologically confirmed colorectal cancer (stage IV, UICC/AJCC staging system) that is not suitable for or cannot be radically resected surgically.
  4. Participants must not have dMMR or MSI-H.
  5. No prior systemic anti-tumor therapy for metastatic colorectal cancer.
  6. have adequate organ function.
  7. The investigator confirms at least one according to v1.1. A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if progression is confirmed.
  8. The Eastern Cancer Cooperative Group () performance score of 0 or 1.

Key Exclusion Criteria:

  1. Received the following treatments or medications prior to starting study treatment:

    1. Received palliative local therapy, non-specific immunomodulatory therapy, or chineses herbal therapy with an anti-tumor indication within 14 days prior to study treatment.
    2. Treatment with systemic (prednisone >10 mg/day or equivalent dose of other glucocorticoids) or other agents within 14 days prior to initiation of study treatment. Note: treatment with local, intraocular, intra-articular, intranasal, and inhaled glucocorticosteroids and short-term prophylactic use of glucocorticoids (e.g., to prevent allergy to contrast agent) are allowed.
  2. Have a major coagulation disorder or other evidence of significant bleeding risk.
  3. Adverse effects of prior antitumor therapy have not returned to a 5.0 grade rating of ≤ grade 1
  4. Have a serious non-healing wound, ulcer, or bone fracture.
  5. History of abdominal fistula, gastrointestinal perforation, or abdominal abscess, history of gastrointestinal obstruction, or clinical signs of gastrointestinal obstruction within 6 months prior to initiation of study treatment.
  6. Severe uncontrollable intra-abdominal inflammation that requires clinical intervention, in the judgment of the investigator.
  7. Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Chemotherapy regimen 1 group - PM8002 Dose 1 + chemotherapy regimen 1

    Subjects will be administered with PM8002 (Dose 1) plus chemotherapy regimen 1 via intravenously (IV) Q2W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 1

  • Experimental
    Chemotherapy regimen 1 group - PM8002 Dose 2 + chemotherapy regimen 1

    Subjects will be administered with PM8002 (Dose 2) plus chemotherapy regimen 1 via intravenously (IV) Q2W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 1

  • Experimental
    Chemotherapy regimen 2 group - PM8002 Dose 1 + chemotherapy regimen 2

    Subjects will be administered with PM8002 (Dose 1) plus chemotherapy regimen 2 via intravenously (IV) and oral administration (PO) Q3W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 2

  • Experimental
    Chemotherapy regimen 2 group - PM8002 Dose 2 + chemotherapy regimen 2

    Subjects will be administered with PM8002 (Dose 2) plus chemotherapy regimen 2 via intravenously (IV) and oral administration (PO) Q3W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 2

  • Experimental
    Chemotherapy regimen 3 group - PM8002 Dose 1 + chemotherapy regimen 3

    Subjects will be administered with PM8002 (Dose 1) plus chemotherapy regimen 3 via intravenously (IV) Q2W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 3

  • Experimental
    Chemotherapy regimen 3 group - PM8002 Dose 2 + chemotherapy regimen 3

    Subjects will be administered with PM8002 (Dose 2) plus chemotherapy regimen 3 via intravenously (IV) Q2W until progression.

    Drug: PM8002 · Drug: Chemotherapy Regimen 3

Interventions

  • DrugPM8002

    IV infusion

    Also known as: BNT327, Pumitamig

  • DrugChemotherapy Regimen 1

    IV infusion

  • DrugChemotherapy Regimen 2

    Oral administration and IV infusion

  • DrugChemotherapy Regimen 3

    IV infusion

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Occurrence and severity of TEAE (treatment emergent adverse event), TRAE(treatment related adverse event), TESAE (treatment emergent serious adverse event), TRSAE (treatment related serious adverse event)

    AEs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in the combination treatment regimen.

    Time frame: From the first dose of the investigational medicinal product (IMP) to the 30-day Safety Follow-Up Visit

Secondary outcomes

  1. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  2. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  3. Time to response (TTR)

    TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieve CR or PR (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  4. Progression free survival (PFS)

    Progression free survival is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    OS is the time from the date of randomization or first dosing date to death due to any cause.

    Time frame: Up to approximately 5 years

Other outcomes

  1. Pharmacokinetic (PK) parameters: maximum concentration

    Maximum plasma concentration \[Cmax\] derived from serum concentrations of PM8002(BNT327) after study drug administration.

    Time frame: Up to 30 days after last treatment

  2. Pharmacokinetic (PK) parameters: minimum concentration

    Minimum plasma concentration \[Cmin\] derived from serum concentrations of PM8002(BNT327) after study drug administration.

    Time frame: Up to 30 days after last treatment

  3. Anti-drug antibody (ADA)

    the incidence of ADA to PM8002

    Time frame: Up to 30 days after last treatment

  4. PD-L1 expression, CD8+ TIL, gene mutations

    PD-L1 expression in tumor and immune cells determined by IHC (immunohistochemistry), rate of CD8+ TIL determined by IHC, gene mutation type (including KRAS/NRAS/BRAF mutation)

    Time frame: Up to approximately 2 years

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 21 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 21, 2025
StartActual
Aug 19, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2030
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07133750
Lead sponsor
Biotheus Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Aug 19, 2025
Primary completion
May 2027 (estimated)
Completion
May 2030 (estimated)
Last update
Jul 23, 2026

Study contacts

Xuelian Xing
Contact
xuelian.xing@biontech.com
+86 18310237570
Ruihua Xu, PhD, MD
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion